Clinical Trials Browser

Enrolling by invitation × INDUSTRY × Bevacizumab × Clear all

NCT05441475 2026-02-25

A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients

Phase 2 Enrolling by invitation

Gastrointestinal

Carcinoma, Hepatocellular